Neurosurgery Focus Issue: – Traumatic Spinal Cord Injury Repair and Regeneration

Manuscript word count (not including table/references): 4244

References: 130

Figures: 4

Tables: 2

Authors: Christopher S. Ahuja1,3,5, Satoshi Nori5, Lindsay Tetreault3, Jefferson Wilson1,3,4, Brian Kwon6,7, James Harrop8, David Choi9, Michael G. Fehlings3,5

Toronto Western Hospital, West Wing 4th floor
399 Bathurst Street, Toronto, ON, M5T 2S8
Tel: 416-603-5675
Fax: 416-603-5298
Email: Michael.Fehlings@uhn.ca

Author Affiliations:

1. Division of Neurosurgery, Department of Surgery, University of Toronto, Toronto, Canada
2. Institute of Medical Science, University of Toronto, Toronto, Canada
3. Department of Surgery, University of Toronto, Toronto, Canada
4. Spine Program, University of Toronto, Toronto, Canada
5. Department of Genetics and Development, University of Toronto, Toronto, Canada
6. Vancouver Spine Institute, Vancouver General Hospital, Vancouver, Canada
7. Department of Surgery, University of British Columbia, Vancouver, Canada
8. Thomas Jefferson University Hospital, Philidelphia, PA

Disclosures: Funded by AOSpine North America

KEYWORDS
Spinal cord injury, trauma, regenerative medicine, stem cells, neuroprotection, management, clinical trial
Introduction

Traumatic spinal cord injuries (SCI) have devastating physical, psychosocial, and vocational implications for patients and caregivers. Direct lifetime costs can reach a staggering $1.1-4.6 million per patient with over 1 million people affected in North America alone (Figure 1)\textsuperscript{1-3}. For treating physicians, a working knowledge of current and emerging therapies in SCI is critical to expediently deliver care and improve long-term functional outcomes for patients\textsuperscript{4, 5}. This article summarizes the evidence-based management of a patient with acute SCI and discusses upcoming neuroprotective and neuroregenerative strategies on the cusp of translation. A primer on the unique pathophysiology of SCI is provided to aid in understanding the rationale behind the diverse range of therapeutic approaches discussed below.

Pathophysiology

Primary and secondary spinal cord injury

SCI can be divided into primary and secondary phases\textsuperscript{6, 7}. The primary SCI is caused by the physical forces of the initial traumatic event and is often the most important determinant of injury severity; physical forces involved can include compression, shearing, laceration and acute stretch/distraction .\textsuperscript{8} After the primary injury event a cascade of secondary injury events is initiated which serves to expand the zone of neural tissue injury and exacerbate neurological deficits\textsuperscript{9, 10}. Secondary SCI is a delayed and progressive tissue injury following the primary SCI. During this secondary injury cascade, inflammatory cells such as macrophages, microglia, T-cells and neutrophils infiltrate the injury site as a result of disruption of the blood-spinal cord barrier . These cells trigger the release of inflammatory cytokines such as tumor necrosis factor (TNF)\textsubscript{α}, interleukin (IL)-1\textsubscript{α}, IL-1\textsubscript{β} and IL-6, with levels of these cytokines peaking 6-12 hours after injury and remaining elevated up to 4 days
after injury\textsuperscript{11}. In addition, a loss of ionic homeostasis after SCI causes increased intracellular calcium, which activates calcium-dependent proteases and causes mitochondrial dysfunction, ultimately leading to cell death.\textsuperscript{12} Notably, oligodendrocytes are susceptible to apoptotic loss. This apoptotic loss has been observed distant from the epicenter of SCI as well as at the lesion epicenter and leads to demyelination of preserved axons.\textsuperscript{13-15} Moreover, phagocytic inflammatory cells release reactive oxygen species (ROS) which causes DNA oxidative damage, protein oxidation and lipid peroxidation. Delayed necrosis and apoptosis are induced by this process.\textsuperscript{16-18} After SCI, upregulated release of excitatory amino acids, such as glutamate and aspartate, is observed due to release from disrupted cells.\textsuperscript{19, 20} The excessive activation of excitatory amino acid receptors produces excitotoxicity and further propagation of loss of neurons and glia by both necrotic and apoptotic cell death.\textsuperscript{21}

**Barriers to regeneration**

It is widely recognized that regeneration in the adult mammalian central nervous system (CNS), which includes the spinal cord, is difficult due to limited plasticity and inhibitory factors produced from myelin degradation.\textsuperscript{22} Although recent progress in the field of SCI research has demonstrated that the CNS has more inherent regenerative capacity than that was once thought,\textsuperscript{23, 24} it does not have the same regenerative capacity that is observed in the peripheral nervous system (PNS). Compared with the PNS, not only is the regenerative capacity of CNS axons lower but it also decreases over time.\textsuperscript{25}

The inhibitory nature of CNS myelin, which is in contrast to PNS myelin, was first recognized in 1985.\textsuperscript{26} Myelin-associated proteins, including neurite outgrowth inhibitor A (Nogo A),\textsuperscript{27, 28} myelin-associated glycoprotein (MAG)\textsuperscript{29, 30} and oligodendrocyte-myelin glycoprotein (OMgp)\textsuperscript{31}, bind Nogo receptors (NgR) that form co-receptor complexes with TNF receptor family proteins such as p75, TROY, and LIGO-1 to activate the GTPase Rho A. Rho-associated protein kinase (ROCK) is the effector of Rho A, which regulates further
downstream effectors, and leads to growth cone collapse of regenerating axons and to neurite retraction.

Hypertrophied astrocytes form a physical barrier called the glial scar, which walls off injured tissue from the healthy tissue. The astrocytes also form a chemical barrier by secreting a number of growth inhibitory chondroitin sulfate proteoglycans (CSPGs) including neurocan, versican, brevican, phosphacan and NG2. Fibroblasts also infiltrate the perilesional region and replace the extracellular matrix (ECM) with fibrous connective tissue. This is associated with the deposition of inhibitory ECM molecules which function as chemical barriers to axonal regeneration similar to myelin associated inhibitors (Figure 2).

Current Management

The current management of SCI largely follows the American Association of Neurological Surgeons (AANS) and Congress of Neurological Surgeons (CNS) joint section guideline series as well as an upcoming AOSpine 2016 guideline (Table 1). Initial care in the field prioritizes securing the airway, breathing, and circulation (ABCs) followed by early recognition of SCI and rapid referral to specialized centers in order to expedite delivery of time-sensitive interventions. To limit further insult to the highly-vulnerable cord, spinal immobilization should be performed for all patients with suspected or confirmed injuries. This typically involves a rigid cervical collar, backboard for transport, and spinal precautions for patient transfers (e.g. logroll maneuver with inline manual cervical stabilization and a transfer board). Systemic hypotension (SBP <90 mmHg), even for brief periods, should be avoided as it is associated with worse long-term neurological outcomes. This can be particularly challenging as hypovolemia is common in polytrauma and interruption of spinal cord sympathetic fibers can induce a profound loss of vascular tone and bradycardia (neurogenic shock). Resuscitation with large-volume crystalloids is typical, however, alpha-
agonists (e.g. phenylephrine) or mixed alpha/beta-agonists (e.g. dopamine, norepinephrine) may also be required as adjuncts. Once resuscitated, an American Spinal Injury Association (ASIA) International Standards for Neurological Classification of SCI (ISNCSCI) examination should be documented to establish baseline function and the level of neurological injury (Table 1; Figure 3)\(^{35}\).

Early localization and classification of osseoligamentous and neurological injuries is critical to expediently provide the outcome-altering therapies discussed below\(^{4,5,36,37}\). The management of particular fracture patterns is discussed in detail in ‘Spine Trauma’. CT imaging is recommended for all patients with suspected SCI as x-rays can miss up to 6% of injuries\(^{38}\). When evaluating patients with high-energy mechanisms and confirmed cervical injuries, thoracolumbar imaging is recommended to rule out concomitant injuries that may not be clinically apparent\(^{39}\). The role of MRI in the initial workup of patients remains unclear, however, urgent MRI is strongly recommended by the senior authors in all cases with unexplained neurological deficits to rule out ongoing spinal cord compression due to occult ligamentous injuries, epidural hematomas, or critical disc herniations. The utility of MRI in prognostication is also becoming more apparent as validated prediction scores continue to be published\(^{40}\).

Concurrent with the diagnostic workup, patients should be transferred to a critical care unit providing continuous respiratory, cardiac, and hemodynamic monitoring\(^{35}\). Immediate life- or limb-threatening injuries should be managed by the appropriate teams while maintaining strict spinal immobilization. Delivering effective care in SCI requires a collaborative multidisciplinary approach including fiberoptic intubation by anesthesia/critical care, modified intraoperative positions for general surgery/orthopedic procedures and early recognition of therapeutic windows which can positively alter long-term outcomes.
Early Surgical Decompression

After SCI, ongoing mechanical compression of the spinal cord can impair blood flow causing ischemia and an expanded zone of neural tissue injury. The goal of early surgical decompression after SCI is to relieve this compression thereby improving the vascular supply to the injured area and limiting the zone of secondary injury expansion. A sizable body of preclinical literature supports the positive effects of early surgical decompression on behavioral and pathological outcomes in animal SCI models.\textsuperscript{41}

With respect to clinical evidence on this topic, a number of comparative cohort studies have been published investigating the clinical impact of performing decompressive surgery prior to several thresholds. Notably, to investigate the efficacy of early decompression prior to a 24 hour threshold, The Surgical Treatment of Acute Spinal Cord Injury Study (STASCIS) prospectively enrolled 313 cervical SCI patients.\textsuperscript{37} Patients receiving early decompression (<24 hours after SCI) experienced 2.8 times greater odds of experiencing an AIS improvement of at least 2-grades at 6 months as compared with patients who underwent late decompression (\(\geq 24\) hours after SCI). Although not statistically significant, there was a trend to a reduced incidence of acute in-hospital complications after early decompression. A prospective Canadian cohort study (including cervical, thoracic and lumbar SCI, n=84) confirmed the findings observed in STASCIS, reporting that in the adjusted analysis early decompression was associated with a statistically greater improvement in ASIA Motor Score recovery at the time of rehabilitation facility discharge.\textsuperscript{42} Moreover, an observational Canadian cohort study showed that AIS A (complete injury) and AIS B (complete motor injury with incomplete sensory injury) patients who received early decompression experienced shorter length of hospital stay, while AIS B, C and D incomplete injury patients decompressed in an early fashion demonstrated an additional 6.3 points in motor recovery as compared to those decompressed late.\textsuperscript{4} Taken together, these findings support the concept of ‘Time is Spine’, emphasizing the importance of early diagnosis and
intervention to enhance long-term outcomes.

Central cord injury is the most common form of incomplete SCI. Historically, early decompression by durotomy and sectioning of the dentate ligaments has been avoided in cases of central cord injury due findings of poor outcomes after surgery. However, an analysis of prospective data performed by the Spine Trauma Study Group associated early decompression (<24 hours after SCI) with an additional 6.3 points of ASIA motor score recovery and 2.8 times odds of ASIA Impairment Scale grade improvement at 12-month follow-up as compared to late decompression (≥24 hours after SCI). In 2013, a randomized control trial Comparing Surgical Decompression Versus Conservative Treatment in Incomplete Spinal Cord Injury (COSMIC; NCT01367405; n=72) trial was initiated by Raboud University. The study will compare surgical decompression within 24 hours to normal conservative treatment without surgery and is currently recruiting participants.

**Steroids for SCI**

Methylprednisolone (MPSS) is a potent synthetic glucocorticoid which upregulates anti-inflammatory cytokine release and reduces oxidative stress to enhance neural cell survival in preclinical models of traumatic SCI. The National Acute Spinal Cord Injury Study (NASCIS) trial series (1990, 1997) found an increase in the number of infection-related complication (e.g. severe sepsis, severe pneumonia) with the high-dose 48-hour protocol which outweighed the potential neurological benefits. However, a shorter 24-hour course of IV MPSS (30mg/kg bolus + 5.4mg/kg/hr x 23hrs) had a substantially lower complication rate and, when administered to a subgroup of patients within 8 hours of injury, was still found to improve neurological outcomes. These subgroup analyses and the purported methodology have been a source of controversy for the last three decades. To definitively address the debate, a 2012 Cochrane Review meta-analysis pooling 6 key randomized trials and observational studies was completed. The study found that patients receiving MPSS within 8 hours of injury had a 4-
point greater ASIA motor score improvement. This modest benefit can have tremendous functional implications for patients when those motor points are recovered in key myotomes such as grip and deltoid function. As a result, an upcoming AOSpine 2016 guideline developed by an international expert panel will suggest 24 hours of IV MPSS be administered within 8 hours of injury to patients without significant medical contraindication.

**Blood Pressure Augmentation**

Vascular injury and localized edema contribute to ongoing ischemia in the perilesional region. Blood pressure augmentation has emerged as a viable strategy to neuroprotect at-risk tissue by enhancing perfusion. Current AANS/CNS guidelines recommend maintenance of mean arterial pressure (MAP) ≥ 85-90mmHg for 7 days post-injury as this has been found to enhance long-term AIS grade outcomes for patients. In application, this most often necessitates invasive blood pressure monitoring, IV fluid therapy and central venous access for continuous infusion of vasopressors. These substantial requirements have prompted a non-inferiority trial entitled Mean Arterial blood Pressure Treatment for Acute Spinal Cord Injury (MAPS; NCT02232165) comparing MAP ≥ 85mmHg vs MAP ≥ 65mmHg with results expected by 2017.

These requirements can also be a significant hindrance to early mobilization, an important component of cardiorespiratory and dermatologic complication prevention. A collaborative interdisciplinary approach utilizing adjunctive measures such as prophylactic vasopressors, abdominal binding, and assistive devices is often required to safely elevate patients. The precise timing of mobilization is dictated by the patient’s hemodynamic status and the expertise of the treating team.

**Key Trials in Neuroprotection**

In addition to early decompression, MAP augmentation and IV MPSS; several other
neuroprotective strategies targeting key components of the secondary injury cascade have emerged in preclinical research. The most promising therapies currently being translated are discussed in this section.

**Pharmacological Therapies**

**Riluzole**

Riluzole is a benzothiazole sodium channel blocker currently approved by the FDA, EMA, and Health Canada for the treatment of amyotrophic lateral sclerosis (ALS) \(^{48,49}\). It protects against excitotoxic cell death by blocking sodium influx in injured neurons and restricting the pre-synaptic release of glutamate \(^{50}\). Animal studies in SCI have demonstrated its ability to reduce neuronal loss and cavity size while improving sensorimotor and electrophysiological outcomes \(^{51-54}\). A collaborative effort to study Riluzole for SCI is being led by the senior author (MGF) and includes the North American Clinical Trials Network (NACTN), AOSpine, the Ontario Neurotrauma Foundation (ONF) and the Rick Hansen Institute. This Phase II/III RCT (N=351) entitled “Riluzole in Spinal Cord Injury Study” (RISCIS; NCT01597518) is currently recruiting patients with acute C4-8 ASIA grade A/B/C injuries and will assess multiple outcomes including the ASIA Impairment Scale (AIS), Brief Pain Inventory (BPI), and Spinal Cord Independence Measure (SCIM) \(^3\). The study is expected to conclude in 2018.

**Magnesium**

Magnesium can act as an NMDA receptor antagonist to decrease excitotoxicity and also functions as an anti-inflammatory agent. Stable CSF levels can be generated by delivering magnesium with an excipient such as polyethylene glycol (PEG) \(^{55-57}\). In animal models, the Mg-PEG combination has been shown to enhance tissue sparing and lead to
behavioral recovery\textsuperscript{58, 59}. A Phase I trial (N=15; NCT01750684) of a Mg-PEG combination (AC105) led by Acorda Therapeutics Inc. concluded in February 2015 with results pending report\textsuperscript{3}.

**Minocycline**

Minocycline is a second-generation bacteriostatic tetracycline antibiotic that has demonstrated neuroprotective properties in preclinical models of CNS disorders including Huntington’s disease and multiple sclerosis\textsuperscript{60, 61}. This stems in part from its significant anti-inflammatory effect mediated by inhibition of microglial activation, interleukin-1β (IL-1β), tumour-necrosis factor-a (TNF-α), cyclooxygenase-2 (COX-2), and matrix metalloproteinases\textsuperscript{62-65}. In animal studies, minocycline treatment after acute SCI has been shown to reduce lesion size and promote tissue sparing\textsuperscript{66, 67}. A Phase II trial demonstrated that patients with acute incomplete cervical SCI (N=25) may benefit from early minocycline administration as they found a 14-point ASIA motor score improvement compared to placebo (p=0.05)\textsuperscript{68}. This exciting result led to the development of a Phase III trial (N=248) entitled ‘Minocycline in Acute Spinal Cord Injury’ (MASC, NCT01828203) which will assess IV minocycline for 7 days versus placebo and is expected to report by 2018\textsuperscript{3}.

**GM-1 Ganglioside**

Monosialotetrahexosylganglioside (GM-1) is a glycosphingolipid found in cell membranes with the ability to activate receptor tyrosine kinases to enhance neural plasticity and regeneration. It has been successfully used for neuroprotection in animal models of SCI where it enhanced tissue sparing\textsuperscript{69}. A successful Phase II trial (N=37) found improved 1-year ASIA motor scores for those receiving daily GM-1 for 18 to 32 days post-injury\textsuperscript{70}. Unfortunately, a follow-up Phase III RCT (N=797) found no statistically significant
improvement with treatment. No further studies have been registered.

Fibroblast Growth Factor

Fibroblast growth factor (FGF) is a heparin-binding protein found to be neuroprotective against excitotoxicity while also reducing oxygen free radical generation. In animal models, it has been shown to reduce motor neuron loss and improve respiratory deficits. A Phase I/II trial (N=62; NCT01502631) of the FGF-analogue, SUN13837 (Asubio Pharmaceuticals Inc.), completed in 2015 with results pending publication

G-CSF

Granulocyte colony-stimulating factor (G-CSF; CSF 3) is a cytokine glycoprotein found in numerous tissues throughout the body. It is capable of promoting cell proliferation, survival, and mobilization. In the CNS, it has been shown to facilitate survival of ischemic cells and reduce inflammatory cytokine expression (e.g. TNF-α, IL-1β). A recent pair of non-randomized Phase I/IIa trials showed no increase in serious adverse events with G-CSF administration while also demonstrating improvement in AIS outcomes. Additional well-designed RCTs will be required to establish the efficacy of G-CSF for SCI.

Hepatocyte Growth Factor

Hepatocyte growth factor (HGF) is a pro-survival, pro-motility c-Met receptor ligand. In small animal SCI models, HGF increases neuron survival and decreases oligodendrocyte apoptosis resulting in improved behavioral outcomes. More recently, HGF has been shown to promote angiogenesis and enhance upper limb recovery in a primate model of cervical SCI. A Phase I/II randomized trial (N=48; NCT02193334) of KP-100IT (HGF; Kringle Pharma Inc.) is now underway with results expected in 2017.
Non-Pharmacologic Therapies

Therapeutic Hypothermia

Therapeutic hypothermia (TH; 32-34°C) significantly reduces the basal metabolic rate of the CNS and decreases inflammatory cell activation\(^83\). It has been successfully applied in neonatal hypoxic-ischemic encephalopathy and after in-hospital cardiac arrest\(^84\)\(^{-}86\). In preclinical SCI models, it has been shown to enhance tissue sparing and promote behavioral recovery prompting a pilot study (N=14) of early systemic TH for patient with AIS A injuries which found no increase in complication rates and a trend towards increased neurologic recovery (43% vs 21%)\(^87\)\(^,\)\(^88\). A Phase II/III trial entitled Acute Rapid Cooling Therapy for Injuries of the Spinal Cord (ARCTIC) has been planned to definitively assess efficacy.

CSF Drainage

CSF drainage attempts to prevent cord hypoperfusion in the critical post-injury period by relieving pressure analogous to EVD drainage for raised ICP. A Phase I/II trial (N=22) completed in 2009 found no significant improvement outcomes with drainage, however, the study was not sufficiently powered to demonstrate efficacy\(^89\). Recent large-animal trials have found CSF drainage acts synergistically with MAP augmentation to improve cord blood flow\(^90\). Based on these key results, a Phase IIB trial (N=60; NCT02495545) of MAP elevation with CSF drainage has been launched with results expected by December 2017\(^3\).

Key Trials in Neuroregeneration

While timely neuroprotective interventions can have tremendous benefits in the acute injury period, the majority of our patients are in the chronic phase of their injuries where further
recovery is limited. This section discusses emerging neuroregenerative therapies in clinical trial or on the cusp of translation (illustrated in Figure 4).

Pharmacological Therapies

Rho-Rock Inhibitor

Components of the injured adult CNS including CSPGs, myelin-associated glycoproteins (MAG), and neurite outgrowth inhibitor (NOGO) potently inhibit axon outgrowth and attempts at regeneration via the Rho-ROCK signaling pathway. Cethrin/VX-210 (Vertex Pharmaceuticals) is a direct Rho inhibitor applied intraoperatively within a fibrin glue sealant to the epidural space. A mixed open-label Phase I/IIa trial (N=48; NCT00500812) of patients with cervical or thoracic injuries found no increase in serious adverse events and a significant improvement in long-term motor scores (18.5 ASIA points) for cervical patients. These very exciting results have led to a Phase III trial in patients with acute cervical SCI planned to begin in 2016.

Anti-NOGO antibody

Anti-NOGO is a monoclonal antibody against NOGO-A, a major inhibitor component of adult CNS myelin. Anti-NOGO treatment delivered by intrathecal injection has been shown to promote axonal sprouting and functional recovery in animal models by clearing the source of this inhibitory signaling. A Phase I trial (N=51; NCT004060160) of humanized anti-NOGO antibody (ATI-355; Novartis) has been completed in Europe with results pending dissemination.

Cell Therapies

Cell-based regenerative therapies are an exciting field as transplanted cells are capable
of filling many roles including providing trophic support, modulating the inflammatory response, regenerating lost neural circuits, and remyelinating denuded axons\textsuperscript{94-96}. Early research utilized embryonic stem cells (ESCs), however, ethical concerns and limited supplies have driven the field towards induced pluripotent stem cell (iPSCs) which can be derived from any somatic cell, including autologous sources\textsuperscript{97}. While unanticipated challenges have arisen, including early senescence and retained epigenetic memory, iPSCs remain a key therapeutic approach moving forward. Numerous animal studies over the last three decades have demonstrated the beneficial effects of a range of transplanted cell types. The most clinically-relevant approaches are discussed here.

**Neural stem/precursor cells**

Neural precursor cells are capable of differentiating to CNS-specific neurons, oligodendrocytes and astrocytes making them a particularly promising strategy. In animal studies, they are capable of integrating with host circuits to enhance behavioral recovery over several weeks\textsuperscript{98, 99}. A pair of phase II trials by Stem Cells Inc. of human CNS stem cell transplants for cervical (N=31; NCT02163876) and thoracic (N=12; NCT01321333) injury were terminated in 2016 prior to completion. While results regarding sensorimotor outcomes are pending dissemination, preliminary data suggest no increase in complications rates related to the treatments\textsuperscript{3}. This provides confirmation of existing safety data that intraparenchymal stem cell transplants are feasible and suggests further optimization of the cells and/or their environment is required to produce meaningful changes in functional recovery.

**Mesenchymal stem cells**

Mesenchymal stem cells (MSCs) are multipotent cells capable of repairing connective tissues by differentiating to myocytes, osteoblasts, chondrocytes and adipocytes\textsuperscript{100}. They can
also modulate local and systemic inflammation which has been exploited in animal models of SCI where MSC treatment led to a decrease in peripheral inflammatory cell infiltration and an increase in parenchymal tissue volume\textsuperscript{101-105}. A Phase II/III RCT (N=32; NCT01676441) by Pharmicell Co. studying intraparenchymal and intrathecal MSC treatment for patients with acute AIS B injuries is ongoing with results expected in 2016\textsuperscript{3}.

**Schwann cells**

The robust regeneration seen in the PNS is thought to be mediated in large part by Schwann cells (SCs). In animal models of SCI, peripheral SCs transplanted into the CNS were found to remyelinate axons, reduce cystic cavitation and enhance recovery\textsuperscript{106}. An open-label Phase I trial (N=10; NCT02354625) by the Miami Project to Cure Paralysis is now investigating SCs in the treatment of patients with chronic AIS A, B, and C cervical or thoracic injuries with results expected by 2018\textsuperscript{3}. The group is also conducted a Phase I trial (N=10; NCT01739023) of autologous SCs for the treatment of subacute thoracic AIS A injuries with results expected by 2016\textsuperscript{3}.

**Olfactory ensheathing cells**

Olfactory ensheathing cells (OECs) protect olfactory neurons exposed to the harsh conditions of the nasal mucosa. They rapidly phagocytose debris and microbes while also providing trophic support through growth factor signaling, and physical axonal guidance through guidance cues\textsuperscript{107-110}. OECs harvested from the nasal mucosa and transplanted into the cord have been shown to improve neurite outgrowth and endogenous remyelination resulting in impressive behavioral recovery in animal models\textsuperscript{111}. Numerous clinical trials of OECs for chronic SCI have been completed worldwide and analyzed in a meta-analysis (cumulative N=1193) which found no significant increase in complication rates related to the transplant\textsuperscript{112}.
However, human OECs have not been well characterized, and transplants invariably consist of mixtures of cells from the olfactory mucosa or bulb. More data is required regarding human cells, which are not as easy to culture in large numbers from patients compared to animal models. Moving forward, higher quality studies will be required to definitively establish the efficacy of OEC therapy.

**Biomaterials**

Regeneration is often hindered by the presence of a substantial post-injury cystic cavity which lacks the substrate to support cell migration and axon growth. Biomaterials have emerged as an exciting strategy to fill cavitation defects and reproduce the complex structural architecture of the extracellular matrix. Many of these materials can be engineered to biodegrade over time, release growth factors, and can even be seeded with stem cells to enhance engraftment. Several biomaterials have been shown to be effective in animal models of SCI from the acute to chronic phases (e.g. HAMC, QL6, fibrinogen, etc.) As the technology evolves, more niche-specific biomaterials are expected to emerge with extended drug-release and cell support capabilities. Currently, a Phase III trial (N=20; NCT02138110) of InVivo Therapeutics’ Neuro-Spinal Scaffold is now recruiting patients with acute AIS A thoracic injuries. Results are expected in 2017.

**Future Directions**

The next substantial changes in the management of patients with SCI are likely to be translated from research which adapts to the heterogeneity of SCI. Modified trial designs which specifically target SCI subpopulations are likely to have the greatest impacts on long-term functional recovery. Stratifying patients in this way will require a combination of existing metrics (e.g. clinical exam, radiography) and novel assessment techniques (e.g. advanced imaging, biochemical biomarkers).
While many novel treatments show promise in animal models of SCI, these experimental paradigms typically involve very controlled injury and recovery conditions after biomechanically precise injuries in animals matched for age, weight, gender, species, and, in some cases, genetic background. This obviously pales in comparison to the natural variability that occurs in the acute human SCI setting. The appreciation of the heterogeneity of human SCI is partly the result of the challenges that have been experienced in the execution of clinical trials of novel therapies, particularly in the acute setting. Variability in neurologic recovery requires that many patients be recruited to complete such acute clinical trials in order to be sufficiently powered. Difficulties in achieving such recruitment has plagued the conduct of virtually all acute clinical studies, and the failure to enroll sufficiently large patient cohorts within realistic time frames has resulted in the premature cessation of numerous clinical trial programs. New approaches to overcome this will be needed in the future to facilitate the conduct of such clinical trials and enhance the speed with which novel treatments for SCI can be validated. Such approaches include narrowing the inclusion window to be more specific in the types and severities of cord injuries being studied, and establishing objective biomarkers for the stratification of injury severity and more precise prediction of neurologic outcome.

Seminal large-scale clinical trials for SCI have typically used broad inclusion criteria to bolster recruitment across participating centers. However, post hoc subgroups analyses have now demonstrated that patient characteristics, presentations, and the underlying pathophysiology in SCI can be highly heterogeneous which can influence the relationship between treatments and outcomes. As a result, more recent studies are recruiting carefully defined populations which we feel is key to success. The upcoming Riluzole in Acute Spinal Cord Injury (RISCIS; NCT01597518) trial is an example where recruitment is limited to patients with C4-8 injuries and ASIA grades A, B, or C. Other clinical initiatives have similarly restricted inclusion both with regards to the level of injury (cervical
vs thoracic), severity of injury (AIS grade A, B, or C), and timing of intervention. While logistically demanding, this careful selection will allow a more valid assessment of the drug’s efficacy.

The next generation of trials will also need to further define subpopulations based on quantifiable imaging and biochemical biomarkers. MRI is a key imaging modality for most CNS pathologies, however, its adoption in SCI has been slow. This is likely because the most common sequences (T1- and T2-weighted) rely on gross measurements of hemorrhage and compression providing only modest utility in predicting outcomes. Future MR imaging will need to quantify the cord microstructure to better estimate damage and recovery potential. Emerging techniques for this include diffusion tensor imaging (DTI; axon integrity), myelin water fraction (MWF; myelination), MR spectroscopy (MRS; gliosis or ischemia), and functional MRI (fMRI; connectivity).

Biochemical biomarkers are also being extensively explored. The Canadian Multicentre CSF Monitoring and Biomarker Study (CAMPER; NCT01279811) is testing CSF over 5 days for inflammatory cell proteins, interleukins, and other cytokines. Specific proteins such as IL-6, S100β, and tau within the cerebrospinal fluid of acute SCI patients have been shown to be able to objectively stratify injury severity and predict AIS grade and motor score improvement. An additional class of biomarkers currently under study through the Rick Hansen Institute is micro RNAs (miRNA) which are short non-coding RNA segments that can regulate post-transcriptional gene expression. miRNAs are specifically up or down regulated with varying grades of SCI and may hold important prognostic information as they are further understood. Together these biomarkers will yield important data to help identify subgroups within the heterogeneous SCI population, and when combined with clinical examination, will allow patients to be stratified by their specific pathophysiologic niche into targeted trials.
The breadth of therapeutic approaches discussed within this review and the rapidly-evolving management of a patient with SCI highlight the excitement and progress continuing to be made in the field by thousands of collaborating physicians, scientists, and allied health workers worldwide.

Acknowledgements

Thank you to AOSpine for funding this work, Madeleine O’Higgins for copyediting and Chi Lam for organizational support.
References


1990;322(20):1405-1411.


59. Kaptanoglu E, Beskonakli E, Solaroglu I, Kilinc A, Taskin Y. Magnesium sulfate treatment
in experimental spinal cord injury: emphasis on vascular changes and early clinical results. 


73. Teng YD, Mocchetti I, Taveira-DaSilva AM, Gillis RA, Wrathall JR. Basic fibroblast growth


86. Hypothermia after Cardiac Arrest Study G. Mild therapeutic hypothermia to improve the


Table 1: “Current best practices for the diagnosis and management of SCI. The table displays several key recommendations, many of which are from the 2013 updated guidelines from the Joint Section on Disorders of the Spine and Peripheral Nerves of the American Association of Neurological Surgeons and the Congress of Neurological Surgeons.” Reprinted with permission from Martin AR, Aleksanderek I, Fehlings MG. Diagnosis and acute management of spinal cord injury: current best practices and emerging therapies. *Current Trauma Reports. 2015;1(3):169-181*

<table>
<thead>
<tr>
<th>Topic</th>
<th>Level of AANS/CNS Recommendation</th>
<th>Guideline/Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypotension</td>
<td>Level III</td>
<td>Correction of hypotension to systolic blood pressure &gt; 90 mm Hg as soon as possible</td>
</tr>
<tr>
<td></td>
<td>Level III</td>
<td>Maintenance of mean arterial blood pressure between 85 and 90 mm Hg for 7 days</td>
</tr>
<tr>
<td>Hypoxia</td>
<td>None</td>
<td>Hypoxia (PaO2 &lt; 60 mm Hg or O2 saturation &lt; 90%) should be avoided [3]</td>
</tr>
<tr>
<td>ICU Monitoring</td>
<td>Level III</td>
<td>SCI patients should be managed in an ICU setting with cardiac, hemodynamic, and respiratory monitoring to detect cardiovascular dysfunction and respiratory insufficiency</td>
</tr>
<tr>
<td>Immobilization</td>
<td>Level II</td>
<td>Patients with SCI or suspected SCI (except in penetrating injury) should be immobilized</td>
</tr>
<tr>
<td></td>
<td>Level III</td>
<td>Spinal immobilization should be performed with rigid cervical collar and supportive blocks on a backboard with straps</td>
</tr>
<tr>
<td>Specialized Centers</td>
<td>Level III</td>
<td>SCI patients should be transferred expeditely to specialized centers of SCI care</td>
</tr>
<tr>
<td>Examination</td>
<td>Level II</td>
<td>The ASIA ISNCSCI examination should be performed and documented</td>
</tr>
<tr>
<td>Imaging</td>
<td>Level I</td>
<td>No cervical imaging is required in awake trauma patients that have no neck pain/tenderness, normal neurological examination, normal range of motion, and no distracting injuries</td>
</tr>
<tr>
<td></td>
<td>Level I</td>
<td>CT is recommended in favour of cervical x-rays</td>
</tr>
<tr>
<td></td>
<td>Level I</td>
<td>CT angiography is recommended in patients that meet the modified Denver screening criteria [9]</td>
</tr>
<tr>
<td>Neuroprotection</td>
<td>Level I</td>
<td>Methylprednisolone is not recommended *</td>
</tr>
<tr>
<td>Spinal Cord Decompression</td>
<td>None</td>
<td>Surgical decompression prior to 24 hours after SCI can be performed safely and is associated with improved neurological outcome [10]</td>
</tr>
<tr>
<td>--------------------------</td>
<td>------</td>
<td>------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Level III</td>
<td></td>
<td>Early closed reduction of fracture/dislocation in awake patients without a rostral injury is recommended, and pre-reduction MRI does not appear to influence outcome</td>
</tr>
</tbody>
</table>

* The authors do not agree with this guideline.
Table 2. Summary of International Standards for Neurological Classification of Spinal Cord Injury

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Motor Score</td>
<td>Score out of 100 points representing motor power in 5 key myotomes (each grade out of 5) in each limb</td>
</tr>
<tr>
<td>Sensory Score</td>
<td>Score out of 224 points representing light touch and pin prick sensation in 28 dermatomes bilaterally</td>
</tr>
<tr>
<td>AIS grade</td>
<td>Cumulative measure of injury severity ranging from AIS grade A (most severe motor sensory complete lesion) to AIS grade E (least severe no neurological deficit)</td>
</tr>
<tr>
<td>AIS grade A</td>
<td>No motor or sensory preservation below the neurological level of injury (including the distal sacral segments)</td>
</tr>
<tr>
<td>AIS grade B</td>
<td>Sensory, but no motor, preservation below the neurological level of injury (including the distal sacral segments)</td>
</tr>
<tr>
<td>AIS grade C</td>
<td>Motor preservation below the neurological level of injury (including the distal segments) with less than half of key muscles below the neurological level graded antigravity or better</td>
</tr>
<tr>
<td>AIS grade D</td>
<td>Motor preservation below the neurological level of injury (including the distal segments) with at least half of key muscles below the neurological level graded antigravity or better</td>
</tr>
<tr>
<td>AIS grade E</td>
<td>Neurological normal in a patients who previously had deficit</td>
</tr>
<tr>
<td>Neurological Level of Injury</td>
<td>The lowest segment where motor and sensory function is normal on both sides</td>
</tr>
<tr>
<td>Zone of Partial Preservation</td>
<td>In AIS grade A patient, lowest dermatome or myotome with partial innervation</td>
</tr>
</tbody>
</table>

Figure 1. Annual incidence of spinal cord injury across reported countries, states/provinces, and regions. Reprinted with permission from Singh A, et al. Clin Epidemiol. 2014;6:309-331.\textsuperscript{130}

Figure 2. Relative annual incidences of countries, states/provinces, and regions. Notes: The red color scheme illustrates incidences of countries. The blue color scheme highlights incidences of states/provinces and regions. Abbreviation: mil, million.
Figure 2. Pathophysiological evolution of spinal cord injury. In the acute injury period (0-48 hrs) hemorrhage, edema, and pro-apoptotic factors (e.g. cytokines, K+, DNA, necrotic debris, etc.) contribute to ongoing cell death. Neurons and oligodendrocytes are injured resulting in further loss of function beyond the initial traumatic insult. Astrocytes rapidly activate, proliferate, and infiltrate the site of injury while depositing chondroitin sulfate proteoglycans (CSPGs) into the microenvironment and release additional pro-inflammatory factors which propagate the injury cascade. Demylinated and injured axons begin to dieback from the inflamed and ischemic perilesional region. In the late subacute and intermediate phases, continued apoptotic and necrotic cell death leave microcystic cavities which eventually coalesce to form formidable barriers to regeneration in the chronic phase (>6 months). The final chronic phase scar is a dynamic entity consisting of a tightly-woven network of astrocytic processes with a dense fibrous deposit of CSPG acting as a physical and biochemical barrier to neurite outgrowth and regenerative cell migration.
Figure 3. International Standards for Neurological Classification of Spinal Cord Injury clinical examination form. The standardized assessment and calculation of motor and sensory scores is demonstrated on this template.

Figure 4 Neuroregenerative strategies for spinal cord injury. Schematic of a traumatic spinal cord injury with demyelination and loss of axons. Regenerative therapies actively being translated are shown including Anti-NOGO-A antibody treatment (e.g. ATI355), Rho-ROCK inhibition (e.g. Cethrin), cell transplants (e.g. iPSC-NPC, ES-NPC, OEC, SC, BMC, MSC), implantation of biomaterials, and mobilization of endogenous cell pools (e.g. Metformin).